Dr. Nina Beri, MD
Claim this profileLaura and Isaac Perlmutter Cancer Center at NYU Langone
Studies Colorectal Cancer
Studies Tumors
10 reported clinical trials
28 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage I
Stage III
2Tumors
dMMR positive
MSI-H positive
Stage IV
Affiliated Hospitals
Clinical Trials Nina Beri, MD is currently running
Nous-209 Vaccine
for Metastatic Cancer
Ref: Protocol v9.0, dated 7Nov2023. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.
Recruiting1 award Phase 1 & 225 criteria
Peposertib + Avelumab + Radiation
for Hepatobiliary Cancer
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving peposertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies.
Recruiting1 award Phase 1 & 210 criteria
More about Nina Beri, MD
Clinical Trial Related6 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Nina Beri, MD has experience with
- Nous-209
- Nivolumab
- Trametinib
- Ipilimumab
- Peposertib
- Avelumab
Breakdown of trials Nina Beri, MD has run
Colorectal Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nina Beri, MD specialize in?
Nina Beri, MD focuses on Colorectal Cancer and Tumors. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage I.
Is Nina Beri, MD currently recruiting for clinical trials?
Yes, Nina Beri, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Nina Beri, MD has studied deeply?
Yes, Nina Beri, MD has studied treatments such as Nous-209, Nivolumab, Trametinib.
What is the best way to schedule an appointment with Nina Beri, MD?
Apply for one of the trials that Nina Beri, MD is conducting.
What is the office address of Nina Beri, MD?
The office of Nina Beri, MD is located at: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York 10016 United States. This is the address for their practice at the Laura and Isaac Perlmutter Cancer Center at NYU Langone.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.